chartexchange

Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update

GlobeNewswire Inc. | Nov 9, 2026 7:22 AM EST

- Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027

Read original article